×
About 2,430 results

ALLMedicine™ Epidermolysis Bullosa Center

Research & Reviews  865 results

Clinical heterogeneity in epidermolysis bullosa simplex with plectin (PLEC) mutations-A...
https://doi.org/10.1002/ajmg.a.62781
American Journal of Medical Genetics. Part A; Vishwanathan GB, Srinivasa M et. al.

May 18th, 2022 - Epidermolysis bullosa simplex (EBS) with plectin mutations is a very rare subtype of EB usually associated with pyloric atresia (PA) or muscular dystrophy (MD). We report six unrelated children between ages 4 and 14 years from India with varied cl...

Genetic Disorders of the Extracellular Matrix: From Cell and Gene Therapy to Future App...
https://doi.org/10.1146/annurev-genom-083117-021702
Annual Review of Genomics and Human Genetics; Chakravarti S, Enzo E et. al.

May 11th, 2022 - Metazoans have evolved to produce various types of extracellular matrix (ECM) that provide structural support, cell adhesion, cell-cell communication, and regulated exposure to external cues. Epithelial cells produce and adhere to a specialized sh...

The impact of epidermolysis bullosa on the family and healthcare practitioners: a scopi...
https://doi.org/10.1111/ijd.16197
International Journal of Dermatology; Chateau AV, Blackbeard D et. al.

May 8th, 2022 - Epidermolysis bullosa (EB) is an inherited genodermatosis that results in mucocutaneous fragility. There is a lack of data on the impact of this disease on parents. There are no studies on the impact on siblings and few on healthcare professionals...

The importance of accurate epidemiological data of epidermolysis bullosa.
https://doi.org/10.1111/bjd.21295
The British Journal of Dermatology; Baardman R, Bolling MC

May 4th, 2022 - The importance of accurate epidemiological data of epidermolysis bullosa.|2022|Baardman R,Bolling MC,|epidemiology,genetics,

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
https://clinicaltrials.gov/ct2/show/NCT03836001

May 3rd, 2022 - The investigator will determine whether more patients taking serlopitant 5 mg daily as compared to placebo can achieve a 3 point or greater reduction in itch severity as measured by numeric rating scale (NRS) score following two months of treatmen...

see more →

Guidelines  1 results

Pain care for patients with epidermolysis bullosa: best care practice guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190576
BMC Medicine; Goldschneider KR, Good J et. al.

Jan 22nd, 2015 - Inherited epidermolysis bullosa (EB) comprises a group of rare disorders that have multi-system effects and patients present with a number of both acute and chronic pain care needs. Effects on quality of life are substantial. Pain and itching are ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  36 results

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
https://clinicaltrials.gov/ct2/show/NCT03836001

May 3rd, 2022 - The investigator will determine whether more patients taking serlopitant 5 mg daily as compared to placebo can achieve a 3 point or greater reduction in itch severity as measured by numeric rating scale (NRS) score following two months of treatmen...

Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis...
https://clinicaltrials.gov/ct2/show/NCT05111600

Feb 16th, 2022 - This trial aims to prove the efficacy and safety of RV-LAMB3-transduced epidermal stem cells and lead to a permanent therapy for the skin lesions affecting JEB patients. Patients are screened according to the Study Inclusion and Exclusion criteria...

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
https://clinicaltrials.gov/ct2/show/NCT02582775

Jan 24th, 2022 - This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched u...

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
https://clinicaltrials.gov/ct2/show/NCT04213261

Dec 14th, 2021 - DEFI-RDEB is a multi-center, intra-patient randomized, controlled, open-label, Phase 3 study of FCX-007 for the treatment of persistent non-healing and recurrent RDEB wounds in approximately 24 subjects. Each subject will serve as his/her own cont...

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
https://clinicaltrials.gov/ct2/show/NCT02810951

Oct 19th, 2021 - RDEB is a rare skin and connective tissue disease characterized clinically by skin fragility with easy blistering, erosion and scarring of skin and mucous membranes, and caused by the deficiency of the protein type VII collagen (COL7). The objecti...

see more →

News  65 results

Topical Treatment for EB Recommended for Approval in the EU
https://www.medscape.com/viewarticle/972788

Apr 27th, 2022 - A topical gel that contains birch bark extract as the active ingredient — Filsuvez (Oleogel-S10) — has been recommended for approval for the treatment of skin wounds in patients with epidermolysis bullosa (EB) by the European Medicines Agency's (E...

Erythema, Blisters, and Scars on the Elbows, Knees, and Legs
https://www.mdedge.com/dermatology/article/235084/dermatopathology/erythema-blisters-and-scars-elbows-knees-and-legs
Kevin G. Sharghi, MD, Patrick S. Rush, DO et. al.

Jan 26th, 2021 - The Diagnosis: Epidermolysis Bullosa Acquisita The diagnosis of epidermolysis bullosa acquisita (EBA) was made based on the clinical and pathologic findings. A blistering disorder that resolves with milia is characteristic of EBA.

Analysis Characterizes Common Wound Microbes in Epidermolysis Bullosa
https://www.medscape.com/viewarticle/943641

Jan 6th, 2021 - Wound cultures from patients with the rare disease epidermolysis bullosa (EB) were most frequently positive for Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA), and Streptococcus pyogenes (GAS) — and antibiotic resistance was common — in a...

Analysis characterizes common wound microbes in epidermolysis bullosa
http://www.mdedge.com/dermatology/article/233973/wounds/analysis-characterizes-common-wound-microbes-epidermolysis-bullosa
Christine Kilgore

Dec 24th, 2020 - Wound cultures from patients with the rare disease epidermolysis bullosa (EB) were most frequently positive for Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA), and Streptococcus pyogenes (GAS) – and antibiotic resistance was common – in a.

FDA Awards Research Grants for 18 Rare Diseases, Including HPV-Related Oropharyngeal Cancer
https://www.onclive.com/view/fda-awards-research-grants-for-18-rare-diseases-including-hpv-related-oropharyngeal-cancer

Dec 4th, 2020 - Gayatri R. Rao, MD, JD Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma, the regulatory agency ...

see more →

Patient Education  4 results see all →